explore -WSS

explore

author：fashion 2025-09-30 20:34:55 - browse：4

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Eli Lilly’s Mounjaro succeeds in second weight

entertainment

WSS

Astellas still sees hope in its gene therapy after four deaths

Gain of function research would be limited under House proposal

The thinking behind the controversial eating disorder chatbot Tessa

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Timeline: Key moments in fight for gay rights

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Hospitals look to new technology to keep health care workers safe

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How to fix the rural physician shortage in the U.S.

Hepatitis C has a cure — but many Americans still lack access to it

Does good food count as health care? Study aims to find out

BioMarin wins approval for gene therapy to treat hemophilia A

Can medical device makers keep up in the race to treat obesity?

Virginia high school admissions case could be legal follow

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

entertainment

In key trial, Verve's treatment lowers cholesterol levels in patients

Reanimated hearts work just as well for transplants, study finds

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Biogen nominates mother of director’s child to replace him on board

Wegovy, Zepbound and weight loss drugs that preserve muscle

Sea level rise could wash away turtle breeding grounds around the world, researchers say

knowledge

Wikipedia

entertainment

Wikipedia